glp-1/fgf21 agonist boehringer GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease Glucagon, GLP-1 and Thermogenesis
Description
161 The results of the Phase II clinical trials of retatrutide were published in The Lancet in 2023
once-weekly in type 2 diabetes: a population pharmacokinetic analysis
10.2337/diabetes.49.4.611 125 WajchenbergB
With over 75% of Policy Labs subscribers suffering from medical conditions associated with obesity, GLP-1 treatment options and clinical studies have been a hot but confusing topic amongst the user base
Analyses were stratified based on the type of control groups and the dosage of tirzepatide
